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ABSTRACT
Objectives To compare the benefits of a tight- 
control/treat- to- target strategy (TC/T2T) in axial 
spondyloarthritis (axSpA) with those of usual care 
(UC).
Methods Pragmatic, prospective, cluster- randomised, 
controlled, open, 1- year trial (NCT03043846). 18 
centres were randomised (1:1). Patients met Axial 
Spondylo Arthritis International Society (ASAS) criteria 
for axSpA, had an Ankylosing Spondylitis Disease 
Activity Score (ASDAS) ≥2.1, received non- optimal 
treatment by non- steroidal anti- inflammatory drugs 
and were biologic- naive.
Interventions (1) TC/T2T: visits every 4 weeks 
and prespecified strategy based on treatment 
intensification until achieving target (ie, ASDAS <2.1); 
(2) UC: visits every 12 weeks and treatment at the 
rheumatologist’s discretion.
Main outcome Percentage of patients with a ≥30% 
improvement on the ASAS- Health Index (ASAS- HI). Other 
efficacy outcomes and adverse events were recorded. A 
health economic evaluation was performed.
Statistical analysis Two- level mixed models were 
used to estimate efficacy outcomes. Cost- effectiveness 
was assessed by the incremental cost per quality- 
adjusted life- year (QALY) gained for TC/T2T versus UC.
Results 160 patients were included (80/group). Mean 
(SD) age was 37.9 (11.0) years and disease duration was 
3.7 (6.2) years; 51.2% were men. ASDAS at inclusion was 
3.0 (0.7), and ASAS- HI was 8.6 (3.7). ASAS- HI improved 
by ≥30% in 47.3% of the TC/T2T arm and in 36.1% 
of those receiving UC (non- significant). All secondary 
efficacy outcomes were more frequent in the TC/T2T arm, 
although not all statistically significant. Safety was similar 
in both arms. From a societal perspective, TC/T2T resulted 
in an additional 0.04 QALY, and saved €472 compared 
with UC.
Conclusion TC/T2T was not significantly superior to 
UC for the primary outcome, while many secondary 
efficacy outcomes favoured it, had a similar safety 
profile and was favourable from a societal health 
economic perspective.
Trial registration number NCT03043846.
Key messages
What is already known about this subject?
 ► Treat- to- target (T2T) has demonstrated to be an 
efficacious approach in rheumatic inflammatory 
diseases such as rheumatoid arthritis and 
psoriatic arthritis.
 ► Recommendations for the management of axial 
spondyloarthritis (axSpA) have been published, 
including the recommendation to apply a T2T 
approach in this disease, despite the lack of 
evidence of the utility of such approach in this 
disease, compared with usual care (UC).
What does this study add?
 ► This is the first study evaluating the efficacy of a 
treat- to- target and tight control (TC) approach 
in axSpA compared with UC.
 ► Overall, in this setting of expert centres in 
spondyloarthritis, UC resulted in very good 
outcomes for a substantial number of patients.
 ► Although the primary outcome measure was 
not achieved, response rates between the two 
treatment groups differed by 11% in favour of 
TC/T2T.
 ► Despite the higher prescription rate of biologics 
in the TC/T2T arm, safety profiles were 
similar across arms, and the TC/T2T arm had 
a favourable outcome from a societal health 
economic perspective.
How might this impact on clinical practice?
 ► This trial did not prove that a TC/T2T approach 
is significantly better than UC for the primary 
outcome, while many secondary efficacy 
outcomes favoured it, had a similar safety 
profile and was favourable from a societal 
health economic perspective at 1 year.
 ► This suggests that a TC/T2T approach might be 
beneficial in axSpA, but other strategy trials for 
this disease aiming to evaluate the efficacy of 
TC/T2Tin this setting are needed to build on our 
findings.
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INTRODUCTION
Disease activity in axial spondyloarthritis (axSpA) is assessed 
by measuring inflammation, with composite indices such as the 
completely patient- reported Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI)1 or the Ankylosing Spondylitis Disease 
Activity Score (ASDAS).2 The ASDAS includes both patient- 
reported outcomes (PRO) and C- reactive protein (CRP), and 
is the preferred outcome for axSpA.3 Moreover, several ASDAS 
thresholds categorising disease activity have been proposed and 
validated: a score <2.1 means low disease activity and ≥2.1 
means active disease.4 5
The ASAS and European League Against Rheumatism 
(EULAR) societies have issued recommendations for the manage-
ment of axSpA6 and indications for the pharmacological inter-
ventions depend on disease activity. The two major categories of 
pharmacological treatments are non- steroidal anti- inflammatory 
drugs (NSAIDs) and biologic disease- modifying antirheumatic 
drugs (bDMARDs), such as tumour necrosis factor inhibitors 
(TNFi) and IL-17 inhibitors (IL- 17i). According to these latest 
recommendations,6 TNFi can be prescribed to patients with 
active disease (evaluated by ASDAS or BASDAI) despite previous 
exposure to at least two NSAIDs for at least 4 weeks in total 
(unless these drugs are contraindicated or cause side effects). 
Moreover, the presence of either objective signs of structural 
damage on pelvic radiography or inflammation (ie, elevated 
CRP or abnormal MRI showing subchondral bone oedema at the 
sacroiliac joint) is required. Finally, the rheumatologist should 
be convinced that in a particular patient there is a favourable 
benefit/risk profile. If the first TNFi fails, a switch to another 
TNFi or IL- 17i should be considered.
According to the treat- to- target (T2T) concept, a precise 
and predefined determination about the target to be reached is 
defined before treatment starts; more importantly, the patient 
and treating physician decide in advance to intensify the treat-
ment until the target is reached, unless contraindicated. The 
concept of tight control (TC) calls for rapid assessment of both 
efficacy and safety of a new treatment in a patient. For safety, 
the time frame can be very short, should an adverse event (AE) 
occur. As part of the TC, the efficacy of NSAIDs for axSpA 
should be evaluated after 4 weeks of treatment and of TNFi and 
IL- 17i after 12–16 weeks.
In medicine, the combination of TC and T2T (a TC/T2T 
strategy) has demonstrated benefits in some areas, in particular 
for hypertension7 and diabetes.8 In rheumatology, this strategy 
has proven to be effective in rheumatoid arthritis9 and psori-
atic arthritis,10 although these trials defined both the target 
and the outcome according to disease activity. In contrast with 
the previous TC/T2T trials in rheumatology, and more in line 
with what has been published in other disciplines, we decided 
to differentiate the target (ie, disease activity) and the outcome 
by choosing as the primary outcome the consequence of disease 
activity (ie, impact on functioning and health).
Conducting trials in which the new treatment algorithm is 
actually a complex strategy can be very challenging, as it may 
be difficult for the staff involved in the study not to apply their 
recently acquired experience with the new treatment algorithm 
into their usual standard of care. One approach to overcome this 
issue is to conduct a cluster- randomised trial. In these studies, 
not patients but centres/investigators are randomised; therefore, 
all individuals belonging to a certain centre are assigned to either 
the new treatment or the usual care (UC). This reduces the like-
lihood of ‘contamination’ of the UC treatment, since no centre 
provides both TC/T2T and UC.11
No trial has yet evaluated the potential benefits of a TC/
T2T strategy for patients with axSpA,12 although experts have 
already recommended using this strategy in daily practice.13 The 
objective of this trial was thus to compare its potential benefits 
with UC in patients with axSpA.
METHODS
Study design
This was a pragmatic, prospective, parallel, cluster- randomised 
(with the centre as the cluster), open, controlled (two arms) trial 
(TICOSPA—NCT03043846). This study was not considered 
interventional, as the treatment was either a standard of care 
approach according to the treating rheumatologist (UC arm) or 
a TC/T2T algorithm strictly following the current international 
scientific recommendations for axSpA management. The study 
duration of 1 year was considered sufficient to demonstrate the 
benefits of a particular strategy on symptoms. The study was 
conducted in agreement with local good clinical practice (GCP) 
and the Declaration of Helsinki.
Participants
Centres/Clusters
The first step was to screen for centres in three European coun-
tries (France, the Netherlands and Belgium). Each centre had 
to be willing to apply the treatment to which they would be 
allocated and thus willing to follow the predefined treatment 
strategy if allocated to the TC/T2T arm. Thus, in order to mini-
mise the chances of protocol violations in the TC/T2T arm, we 
selected centres with a particular interest in spondyloarthritis 
and that were interested in the potential efficacy of T2T and 
would be willing to follow the TC/T2T algorithm if randomised 
to this arm. Before randomisation, all selected centres signed a 
written agreement to adhere to their allocated strategy.
Patients
Patients had to be adults younger than 65 years, with a diag-
nosis of axSpA according to their rheumatologist and fulfilling 
the ASAS classification criteria for axSpA.14 At inclusion, disease 
had to be active (ie, ASDAS ≥2.1). In addition, patients should 
not have been optimally treated with NSAIDs (ie, they could 
not have received two full courses of NSAIDs at a daily full 
dose for at least 2 weeks each) and should not have contrain-
dications to NSAIDs, be biologic- naive and not have received 
apremilast in the past 3 months. They also had to have a pelvic 
radiography and MRI of the sacroiliac joints available, as well 
as their HLAB27 status. All patients needed to understand the 
study objectives and to complete questionnaires. They also had 
to provide written consent.
Treatments
TC/T2T arm
Visits were scheduled every 4 weeks, and the strategy was 
prespecified, based on the current recommendations for axSpA 
management,6 compiled in an electronic algorithm that guided 
treatment decisions at each visit, after collection and entry of 
the ASDAS in the electronic case report form (CRF). The target 
was an ASDAS <2.1 (ie, low disease activity4); although remis-
sion has been proposed as the preferred target in recommenda-
tions, low disease activity has been proposed as an alternative: an 
ASDAS <2.1 was selected by the steering committee as <1.3 was 
considered too stringent. If the target was not met, intensifica-
tion of treatment was proposed to the investigator until the target 
was met. In all cases, but in particular with regard to bDMARD 
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prescriptions, the recommendation had to be consistent with the 
product labelling. If the recommendation was to initiate a TNFi, 
the investigator chose which TNFi to use, considering the coun-
try’s reimbursement criteria. For the specific case of bDMARDs, 
safety was evaluated every 4 weeks, but, according to recom-
mendations, efficacy (ie, whether ASDAS target was met) was 
evaluated at the visit occurring after at least 12 weeks after initi-
ation. When the target was met, treatment continuation was 
recommended; if the patient was considered to have inactive 
disease (ie, ASDAS <1.3), acceptance of any recommendation to 
taper NSAIDs was based on a shared decision with the patient. 
The full algorithm providing the predetermined recommenda-
tions at each visit is available in online supplemental file 1 and 
also in the Protocol.
Usual care
Visits to assess study outcomes were scheduled every 12 weeks, 
and all treatment decisions, including frequency of follow- up, 
were left to the investigator’s discretion.
Outcomes
All outcomes were assessed at the patient level.
Efficacy outcomes
Primary outcome: The validated ASAS- Health Index (ASAS- HI) 
is a 17- item questionnaire (range 0–17, with 17 representing 
the worst health) that represents the most important items of 
the ASAS Core Set of the International Classification of Func-
tioning as well as five patient- reported outcome (PRO) items.15 
The primary outcome of the trial was the percentage of patients 
achieving an improvement of at least 30% in the ASAS- HI at the 
1 year visit.
Secondary efficacy outcomes can be categorised in two groups: 
(1) Disease activity outcomes: ASDAS over time, ASDAS states 
(ie, low disease activity (LDA) and inactive disease (ID)) and 
changes (ie, major improvement (MI) and clinically important 
improvement (CII)),4 5 ASAS responses (ASAS20, ASAS40),16 
ASAS partial remission, BASDAI, BASDAI 50,17 Physician 
Global Assessment and CRP; (2) other PRO measures (Bath 
Ankylosing Score Global (BASG),18 Patient’ global assessment of 
disease activity, Visual Analogic Scale (VAS) of Fatigue), func-
tioning and health (ASAS- HI as a continuous score, BASFI19 and 
EQ- 5D- 5L20), work impairment (Work Productivity and Activity 
Impairment Questionnaire, WPAI),21 and treatment (ASAS- 
NSAID score,22 which aims to quantify the NSAID intake in a 
defined period of time, and bDMARD initiations).
Safety outcomes 
All adverse events (AEs) that were cardiovascular, gastrointes-
tinal or related to infections or allergies during patients’ partic-
ipation in the study were collected and recorded in the case 
report form, in accordance with EULAR recommendations.23
Resource utilisation and costs (cost–utility analysis)
At each visit, cost questionnaires were added, assessing health-
care resource utilisation (rheumatologist and other specialist 
visits, nurse, physiotherapist, and emergency department visits, 
and days in rehabilitation centres and hospitals) and work days 
(of paid work) missed in the past 12 weeks. Costs per healthcare 
resource category over the 48- week follow- up were calculated by 
multiplying the resource used by the Dutch unit costs, taken from 
the Dutch guideline for economic evaluations, and expressed in 
2019 Euros24 (online supplemental file 4). Productivity losses 
were valued by using the human capital method in the base- case 
analysis.
No structural- progression outcomes were evaluated in this 
study, as the 1- year period was deemed too short to observe any 
effect.
Sample size estimation
Sample size was calculated in two consecutive steps.
First step: The cluster design was not considered (ie, this calcu-
lation used a conventional approach, considering that randomi-
sation would occur at the patient level). It was anticipated that 
in the UC arm, 25% of the patients would meet the definition 
of response (≥30% improvement in the ASAS- HI score after 
1 year of follow- up). For an α risk of 5% and a β risk of 80%, 
with a bilateral test, 77 patients per arm were needed to demon-
strate a 20- percentage- point difference among responders, that 
is, at least a 45% responder rate in the TC/T2T arm if the UC 
responder rate was 25%. For a uniform number of patients per 
centre, we aimed for a total sample of 160 patients (80 per arm).
Second step: The cluster- randomised design was considered 
by multiplying the estimated sample needed (ie, 160 patients) 
by an ‘inflation factor’ defined as 1+(m−1)*ρ, where m is equal 
to the size of the cluster (in our study, the number of patients 
per centre=10) and ρ is the intracluster correlation, usually set 
at 0.05.25 The inflation factor for our study was 1.45, and thus 
the sample needed to take the cluster- randomised design into 
account was 232 patients (116 patients per arm).
Randomisation and blinding
The 1:1 randomisation was cluster- based: a random number 
table was used to randomise centres instead of individuals. 
Centres allocated to the UC arm were blinded for the specific 
TC/T2T strategy (including treatment and frequency of assess-
ments) in this trial until the end of the study. Separate investi-
gator meetings on different days were organised for each arm.
This was an open study in the sense that centres were not 
blinded to the study arm to which they were allocated. Within 
each centre, consecutive patients meeting the inclusion criteria 
were screened and invited to participate: patients were not 
blinded but received different information letters, depending on 
the allocation of the centre in which they were included (one 
explaining the TC/T2T strategy and visit schedules, and the 
other the UC visit schedule).
Statistical methods
All statistical analyses were performed with the open- source 
software R, V.3.5.2,26 and Stata SE release V.14.0.
The analysis population was the intention- to- treat population.
Efficacy analysis
A cluster- randomisation design must consider two main limita-
tions. The first is that observations of groups of individuals from 
the same cluster have a lower variance. To take this into account, 
all the efficacy analyses first used a two- level mixed model with 
two random effects to estimate the percentage of responders or 
the change in outcome over the follow- up (ie, a cluster- adjusted 
model). The second limitation is that in this type of trial, rando-
misation occurs at the cluster level, while outcomes are assessed 
at the individual (patient) level. Therefore, to compensate for 
the potential imbalance of some covariates across treatment 
groups, we identified those that were not balanced and included 
them as adjustment factors in a second model otherwise identical 
to the first (ie, cluster and imbalance- adjusted model, presented 
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in detail in online supplemental file 3). The use of mixed- 
effects models enabled us to deal with the missing data by using 
maximum likelihood.27
Safety analysis
The number and types of AEs were described both globally and 
by study arm, as recommended by EULAR28 for cardiovascular, 
infection- related and gastrointestinal events, as well as allergy 
(skin reactions and anaphylaxis).
Cost–utility analysis
A health economic evaluation from the perspectives of health-
care and of society (including also costs related to sick leave) was 
performed. In the base case, cumulative costs and time- averaged 
health utilities were calculated for each patient after multiple 
imputation of missing cost categories and EuroQol 5 domains 
and 5 levels (EQ- 5D). Next, the incremental costs (iCosts) and 
effects (quality- adjusted life- years, iQALY) were used to calcu-
late the incremental cost per QALY gained (incremental cost–
utility ratio or ICUR; ICUR=iCosts/iQALY) and incremental 
net monetary benefit (iNMB; iNMB=iQALY*[willingness- 
to- pay threshold]–iCosts). To account for baseline differences 
in costs and QALYs between the study arms, these incremental 
costs and QALYs were baseline- adjusted by using seemingly 
unrelated regressions (SUREG). With SUREG, costs and effects 
can be modelled jointly within the same model, thereby taking 
their (expected) correlation into account.29 30 For this analysis, 
SUREG was used with a robust variance estimator to reflect the 
clustering of the data. Finally, the conventional non- parametric 
bootstrapping method was considered inappropriate for esti-
mating the CIs of the ICUR and cost- effectiveness acceptability 
curves, because it ignores the clustering of patients inherent 
to a cluster- randomised clinical trails (RCT). Instead, two- 
stage bootstrapping, which resamples clusters (first stage) and 
individuals (second stage), was performed.31 32 As the cluster 
sizes were not balanced, a modified version33 that allows for 
this imbalance was used to resample the current study popula-
tion 5000 times. In addition to the base- case analysis, several 
sensitivity analyses were conducted. These assessed the impact 
of reducing bDMARD costs, a different valuation method for 
productivity losses (the friction cost approach, which considered 
only productivity losses during the 13- week friction period), 
the inclusion of costs of presenteeism (at- work productivity 
loss) and utility based on ASAS- HI (instead of EQ- 5D).34 For all 
analyses, both the societal perspective (including all costs) and 
the healthcare perspective (including only healthcare costs and 
excluding productivity losses) are presented. The willingness- 
to- pay threshold used to interpret the ICUR and to calculate the 
iNMB was set at €20 000/QALY, based on the level of health 




Eighteen centres (4 in Belgium, 10 in France and 4 in the Neth-
erlands), all of them rheumatology departments with an exper-
tise in SpA, were invited and agreed to participate. All centres 
signed an agreement to follow the treatment to which they were 
allocated. After randomisation, nine centres were allocated to 
the TC/T2T arm and nine to the UC arm.
During the recruitment period (from February 2017 to June 
2019; dataset locked on August 2019), centres from the TC/
T2T arm screened and included 80 patients, while centres from 
the UC arm screened 83 patients and included 80. The anal-
ysis population comprised 160 patients. After 1 year, one centre 
(UC arm) had not included any patient. At the patient level, in 
the TC/T2T arm, seven patients were lost to follow- up and one 
refused to continue the study; in the UC arm, three patients 
were lost to follow- up, four refused to continue and one was 
excluded because of a non- spondyloarthritis diagnosis during 
follow- up. In total, 144 patients (72 per arm) completed the 
last visit (figure 1 presents the study flow diagram, and online 
supplemental file 2 presents the flow diagram of the study at the 
cluster level).
Baseline data
The patients’ mean age (SD) was 37.9 (11.0) years with a mean 
disease duration of 3.7 (6.2) years; 51.2% were men. Radio-
graphic damage of the sacroiliac joints was found in 46.9% of 
patients, 81.9% had had MRI- positive sacroiliitis at least once, 
and 75.0% were HLA- B27+. Mean ASDAS at inclusion was 
3.0 (0.7) and mean ASAS- HI was 8.6 (3.7). The study design 
resulted in a significant baseline imbalance of some variables at 
the patient level: patients from the TC/T2T arm had a univer-
sity education, a history of anterior uveitis and a higher Physi-
cian Global Assessment significantly more often; they had a 
history of gastrointestinal events related to NSAID intake less 
often and fewer mean days in rehabilitation facilities in the 3 
months before the study (see online supplemental file 3). These 
variables were therefore included as adjustment variables in the 
‘cluster and imbalance- adjusted model’. Baseline characteristics 
are presented in table 1.
Efficacy outcomes
The estimated percentages of patients achieving an improvement 
≥30% on the ASAS- HI at the 1 year visit with the ‘cluster and 
imbalance- adjusted model’ was 47.3% in the TC/T2T arm and 
36.1% in the UC arm. The estimated difference (11.2%, 95% CI 
8.5% to 13.9%) was not statistically significant in either model 
(p=0.094 and p=0.079 for the ‘cluster- adjusted’ and ‘cluster 
and imbalance- adjusted’ models, respectively). Some estimated 
efficacy outcomes were significantly favouring the TC/T2T 
arm, for example, 76.5% vs 59.5% (p<0.05 with both models) 
for ASDAS low disease activity and 52.3% vs 34.7% (p<0.05 
with both models) for the ASAS40 at 1 year (figure 2), but the 
majority did not reach a statistical significance (table 2). The 
ASAS- NSAID score was not significantly different between treat-
ment arms. The prescription rate for biologics was initially lower 
in the TC/T2T arm, but was quickly (ie, within 30 days) signifi-
cantly higher among these patients (56.2% vs 27.2%, p<0.01; 
online supplemental file 5).
Safety
Overall, 55 AEs were reported, 33 in the TC/T2T and 22 in the 
UC arm. The TC/T2T arm had more allergies (8 vs 1) mainly 
because of local skin reactions at the injection site. Both groups 
had a similar number of infections (15 vs 16 in the TC/T2T and 
UC arms, respectively), with 2 of them severe, both in the UC 
arm. Table 3 summarises all the AEs.
Cost–utility analysis
During this 48- week follow- up, there were more visits to rheu-
matologists and more days of bDMARDs used, but fewer visits 
to physical therapy, fewer days of rehabilitation care and espe-
cially fewer days of sick leave in the TC/T2T arm (online supple-
mental file 4).
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In the unadjusted base- case analysis, TC/T2T dominated UC 
(iQALY 0.07; iCosts −€1472) from a societal perspective and 
was cost- effective with an ICUR of €11 538 (iQALY 0.07; iCosts 
€801) from a healthcare perspective. The baseline- adjusted and 
cluster- adjusted base- case analysis produced similar results, with 
TC/T2T dominating UC and being cost- effective with an ICUR 
of €19 430 from the societal and healthcare perspective, respec-
tively. In bootstrapped adjusted analyses, the probability that TC/
T2T would be cost- effective compared with UC was 72% from 
the societal perspective and 52% from the healthcare perspec-
tive, given a threshold for willingness- to- pay of €20 000/QALY.
In the sensitivity analyses, lower bDMARD costs favoured TC/
T2T even more strongly, as expected. The estimate of produc-
tivity costs based on the friction cost approach (ie, considering 
only the first 13 weeks of absence) still favoured TC/T2T, as did 
inclusion of the presenteeism costs (ie, productivity loss while at 
work), both somewhat less strongly than the base case. Finally, 
using disease- specific utilities based on the ASAS- HI instead of 
the EQ- 5D to calculate QALYs resulted in less favourable results 
for TC/T2T due to the smaller gain in QALYs (0.015–0.018) for 
TC/T2T relative to UC (table 4 and online supplemental file 4).
DISCUSSION
This is the first strategy trial evaluating the potential benefits of 
a TC/T2T strategy in patients with axSpA. This was a negative 
trial, in which the main outcome did not reach a statistically 
significant difference in both groups. Safety was similar in both 
arms, even though biologics were prescribed significantly more 
often in the TC/T2T arm and produced more local injection 
site allergic reactions in this arm. The health economic analysis 
also favoured the TC/T2T arm from the societal perspective and 
(although with a lower level of certainty) from the healthcare 
perspective as well.
Nevertheless, in almost all of the estimated efficacy outcomes 
scores and responses were in favour of the TC/T2T, even if most 
did not reach a statistical significance. Therefore, it is important 
to analyse the reasons behind the lack of a statistically significant 
difference between the groups for the main outcome measure. 
While some would consider this a negative trial and would argue 
that no further efficacy endpoints should be interpreted, this 
approach has been considered by some as overly simplistic in 
Figure 1 Flow chart of the study. ASDAS, Ankylosing Spondylitis Disease Activity Score; SpA, spondyloarthritis; TC/T2T, tight control and treat- to- 
target; UC, usual care.








Age (years)* 37.6 (10.8) 38.1 (11.4) 37.9 (11.0)
Sex (Male) 45 (56.2%) 37 (46.2%) 82 (51.2%)
Smoking status (current) 29 (36.2%) 32 (40.0%) 61 (38.1%)
University studies † 57 (71.2%) 42 (52.2%) 99 (61.9%)
Disease duration (years) 4.2 (6.56) 3.3 (5.83) 3.7 (6.20)
Radiographic sacroiliitis 42 (52.5%) 33 (41.2%) 75 (46.9%)
MRI sacroiliitis 63 (78.8%) 68 (85.0%) 131 (81.9%)
HLA B27 positive 62 (77.5%) 58 (72.5%) 120 (75.0%)
History of anterior uveitis† 16 (20.0%) 6 (7.5%) 22 (13.8%)
Good NSAID response 63 (78.8%) 55 (68.8%) 118 (73.8%)
ASDAS 3.0 (0.7) 3.0 (0.6) 3.0 (0.7)
BASDAI (n=80/79) 5.2 (1.7) 5.2 (1.9) 5.2 (1.8)
CRP (mg/L) 9.2 (9.8) 7.4 (10.5) 8.3 (10.1)
ASAS- Health Index (0–17) 
(n=80/78)
8.2 (3.8) 9.0 (3.6) 8.6 (3.70)
NSAID score (last 3 months) 32.7 (35.4) 37.5 (36.6) 35.1 (36.0)
*Numerical variables are presented as means (SD) and categorical variables as n 
(percentage).
†Significantly imbalanced variables; other imbalanced variables at baseline were 
gastrointestinal events in relation to NSAIDs, Physician Global and Rehabilitation 
days (see online supplemental file 3).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; CRP, C- reactive protein; NSAID, non- steroidal 
anti- inflammatory drugs.
copyright.













is: first published as 10.1136/annrheum





6 Molto A, et al. Ann Rheum Dis 2021;0:1–9. doi:10.1136/annrheumdis-2020-219585
Spondyloarthritis
the literature,36 and in some cases, the presentation of all results 
is needed to guide appropriate clinical interpretation of the 
findings.
The first reason behind our not statistically significant 
results may be related to the choice of the outcome measure: 
in most strategy trials the target is usually defined by a relevant 
threshold in a factor that predisposes patients to that outcome, 
below which the risk of developing this outcome is abolished 
or significantly reduced. A good example of this can be found 
in a TC/T2T strategy in diabetes that aimed for a target of 
glycosylated haemoglobin below 7% and used a decreased 
rate of diabetic retinopathy as the primary objective.11 Inter-
estingly, in the two published T2T trials in rheumatology, the 
TICORA9 and TICOPA10 trials, both the outcome and the target 
were ‘disease activity- related’, that is, Disease Activity Score 28 
(DAS28) and EULAR response in TICORA and minimal disease 
activity and American College of Rheumatology (ACR) 20 in 
TICOPA. To avoid the potential circularity, in TICOSPA the 
target was disease activity but the main outcome was a conse-
quence of disease activity, that is, disease- specific functioning 
Figure 2 ASAS- HI improvement ≥30%, ASDAS LDA status and ASAS40 response estimated at 48 weeks. *Statistical significance. ASAS- HI, Axial 
Spondyloarthritis International Society- Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; LDA, low disease activity; T2T/TC, treat- to- 
target and tight control; UC, usual care.
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and health, measured by ASAS- HI. Furthermore, others may 
consider that our outcome was not ambitious enough and we 
should have aimed at reducing structural damage, like retinop-
athy for diabetes8 or cardiovascular events (such as myocardial 
infarction or stroke) for hypertension.7 However, keeping in 
mind the lower prevalence of axSpA (compared with diabetes 
and hypertension) and the slow progression rate in axSpA nowa-
days, it would have been very difficult to run such TC/T2T trial 
in axSpA.
Another reason behind this lack of statistically significant 
difference is the unexpected good results of the UC arm: in 
our initial hypothesis, we expected a 25% response in the UC 
group, while UC presented a 36% response rate. This can be 
explained by the open cluster- trial design, as only SpA expert 
centres, aware of the need for such a trial and of the TC/T2T 
recommendations could be selected to participate, and were 
thus probably applying recommendations in their ‘usual care’. 
Also, we calculated the expected treatment effect as if the study 
was a trial against placebo (in which a 20% difference is usually 
used). Here, patients from the control group were not receiving 
a placebo. In the rheumatology literature, a 12% difference in 
response between two active- treatment groups has been set as 
the difference to be observed in non- inferiority head- to- head 
trials.37–39
Alternatively, there is also the possibility that this trend 
observed across efficacy outcomes in favour of TC/T2T is not 
due to a true- positive effect but is either non- clinically rele-
vant or only reflecting a higher placebo effect on the TC/T2T 
arm. Indeed, patients and centres were not blinded to the arm 
of treatment they were allocated to: patients from the TC/T2T 
arm received an information sheet in which it was stated that 
they would be receiving the ‘state- of- art’ of treatment, strictly 
following current recommendations; as all efficacy outcomes 
are patient- reported, it is also possible that the observed and 
estimated differences in favour of TC/T2T are only reflecting a 
placebo effect.
Nevertheless, in an era of cost- containment, the cost- utility 
analysis favoured the TC/T2T strategy, especially from the 
societal perspective. Results of the economic evaluation were 
different from those observed in the TICOPA10 trial, where 
the active arm was significantly more expensive than the UC 
arm, despite iQALYs similar to those in TICOSPA. This might 
be explained by the partial offset in TICOSPA of the extra cost 
of bDMARDs and visits by the substantially lower costs due to 
reduced numbers of days of sick leave and of visits for physio-
therapy and rehabilitation facilities. The costs per unit of the 
different health resources, such as visits to the rheumatologist, 
varied according to the study setting: the UK for TICOPA, 
compared with Dutch true costs, adjusted for purchasing power 
parities for Belgium and France, for TICOSPA. This might have 
driven differences between the studies and limited compari-
sons. Furthermore, with the arrival of biosimilars, the costs of 
bDMARDs decreased substantially compared with TICOPA. 
Moreover, patients from the UC arm used rehabilitation and 
physical therapy more often at baseline, and this trend continued 
during the study. Our cluster- randomisation design of the trial 
may explain this difference: different habits in different centres 
may have led to differences in costs.
Overall, in this setting of expert centres in SpA, UC resulted 
in very good outcomes for a substantial number of patients. 
Although the primary outcome measure was not achieved, with 
response rates between the two treatment groups differed by 
11% in favour of TC/T2T. Despite the higher prescription rate of 
biologics in the TC/T2T arm, safety profiles were similar across 
arms, and the TC/T2T arm had a favourable outcome from a 
Table 2 Estimated efficacy outcomes at the last study visit (week 48)
Estimated outcomes at week 48
Cluster- adjusted model
Cluster and imbalance- 
adjusted modelTC/T2T UC
ASAS- HI significant improvement 47.3% 36.1% NS NS
ASDAS LDA 76.5% 59.5% <0.01 0.03
ASDAS ID 25.9% 18.7% NS NS
ASDAS CII 61.2% 46.0% <0.01 0.02
ASDAS MI 16.5% 14.9% NS NS
ASAS40 52.3% 34.7% <0.01 0.01
ASAS20 94.9% 85.9% <0.01 0.03
BASDAI 50 79.0% 43.8% 0.01 0.03
Physician Global (0–10) 2.0 (0.2) 1.8 (0.2) NS NS
CRP (mg/L) 3.9 (1.4) 3.5 (1.5) NS NS
BASG (0–10) 2.6 (0.5) 3.4 (0.5) NS NS
BASFI (0–10) 1.7 (0.5) 2.4 (0.5) NS NS
EQ5D- 5L 0.7 (0.1) 0.8 (0.1) 0.02 NS
ASAS- NSAID score 1.5 (2.2) −4.9 (2.9) NS NS
ASAS- HI, ASAS- Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CII, clinically important 
improvement; EQ5D, EuroQol 5 domains and 5 levels; ID, inactive disease; LDA, low disease activity; MI, major improvement; NS, non- significant.







Total number of adverse events 55 33 22
Cardiovascular events 0 0 0
Allergies 9 8 1
Skin, local reaction 7 6 1
Anaphylactic reaction 2 2 0
Infection 31 15 16
Opportunistic infections 2 0 2
Viral 22 12 10
Severe infections 2 0 2
Gastrointestinal events 12 7 5
UC, usual care.
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societal health economic perspective. This suggests that a TC/
T2T approach might be beneficial in axSpA, but other strategy 
trials for this disease aiming to evaluate the efficacy of TC/T2Tin 
this setting are needed to build on our findings.
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Table 4 Cost–utility analyses
Perspective Adjustment iCosts iQALY ICUR iNMB* p20† p50†
Base- case analyses     
Unadjusted Societal None −€1472 0.069 Dominates UC €2860 0.85 0.92
Adjusted Healthcare None €801 0.069 €11 538/QALY (NE) €587 0.69 0.91
Societal Baseline costs/effects −€472 0.041 Dominates UC €1295 0.72 0.83
Healthcare Baseline costs/effects €789 0.041 €19 430/QALY (NE) €23 0.52 0.78
Sensitivity analyses
bDMARD discount (25%) Societal Baseline costs/effects −€856 0.041 Dominates UC €1678 0.78 0.86
Healthcare Baseline costs/effects €406 0.041 €9888/QALY (NE) €415 0.68 0.86
bDMARD discount (50%) Societal Baseline costs/effects −€1239 0.041 Dominates UC €2060 0.82 0.88
Healthcare Baseline costs/effects €23 0.042 €553/QALY (NE) €809 0.86 0.91
ASAS- HI utility Societal Baseline costs/effects −€466 0.018 Dominates UC €817 0.64 0.67
Healthcare Baseline costs/effects €793 0.015 €51 938/QALY (NE) −€487 0.29 0.48
Friction cost approach‡ Societal Baseline costs/effects €183 0.042 €4400/QALY (NE) €648 0.63 0.79
Costs of presenteeism included Societal Baseline costs/effects −€876 0.040 Dominates UC €1679 0.67 0.76
*For lambda (willingness- to- pay threshold)=€20 000/QALY.
†Probability that TC/T2T is cost- effective for willingness- to- pay thresholds (lambda) of €20 000/QALY or €50 000/QALY (p20 or p50, respectively).
‡For the friction cost approach, absenteeism (sick leave) that lasts longer than the friction period (13 weeks) is not included in the costs.
iCosts, incremental costs; iQALY, incremental QALY; NE, northeast (position of intervention in cost- effectiveness plane, comparator at centre [0,0].
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